Form D · Pharmaceuticals
Cerimon Pharmaceuticals, Inc.
South San Francisco, CA · CIK 0001329473
Offering snapshot reported Nov 15, 2010 · SEC filing
- Reported sold
- $233K Offering amount: $250K
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 1, 2010 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$750,000 → $232,957
- Reported investors10 → 9
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 15, 2010 | Amendment | $232,957 | -$517,043vs Apr 2, 2010 | 9 | SEC filing |
| Nov 15, 2010 | Amendment | $232,957 | -$517,043vs Apr 2, 2010 | 9 | SEC filing |
| Jun 24, 2010 | Amendment | $1,000,000 | $250,000vs Apr 2, 2010 | 10 | SEC filing |
| Apr 2, 2010 | Initial | $750,000 | No comparison | 10 | SEC filing |
| Sep 9, 2009 | Initial | $1,500,003 | No comparison | 10 | SEC filing |
| Nov 1, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jun 6, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-77816
Series A-2 Preferred Stock and the underlying shares of Common Stock issuable upon conversion.
Source: Form D, filed Nov 15, 2010. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Adelman | Director |
| Ansbert Gadicke | Director |
| Paul Hastings | Director |
| Vaughn Kailian | Director |
| Matthew J. Meyer | Executive |
| Gary Patou | Executive |
| Denise Pollard Knight | Director |
| James S. Shannon | Director, Executive |
| James H. Welch | Executive |
| Samuel P. Wertheimer | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
701 Gateway Blvd., #100
South San Francisco, CA, 94080
South San Francisco, CA, 94080